A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

被引：0
|
作者：
Das, Satya [1 ]
Du Liping [1 ]
Schad, Aimee [2 ]
Jain, Shikha [3 ]
Jessop, Aaron [1 ]
Shah, Chirayu [1 ]
Eisner, David [1 ]
Cardin, Dana Backlund [4 ]
Ciombor, Kristen Keon [1 ]
Goff, Laura Williams [1 ]
Bradshaw, Marques [1 ]
Delbeke, Dominique [1 ]
Sandler, Martin P. [1 ]
Berlin, Jordan [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[3] Univ Illinois, Coll Med, Chicago, IL USA
[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.363
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
363
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Validation of a Clinical Score (CS) for Patients With Well-Differentiated Neuroendocrine Tumors (WD NETs) Under Consideration for Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Dotatate
    Das, Satya
    Chauhan, Aman
    Du, Liping
    Thomas, Katharine E.
    Jacob, Aasems
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana B.
    Ciombor, Kristen K.
    Goff, Laura W.
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin
    Berlin, Jordan
    Ramirez, Robert A.
    [J]. PANCREAS, 2022, 51 (03) : E41 - E41
  • [2] Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.
    Das, Satya
    Chauhan, Aman
    Du, Liping
    Thomas, Katharine
    Jacob, Aasems
    Schad, Aimee
    Jain, Shikha
    Jessop, Aaron
    Shah, Chirayu
    Eisner, David
    Cardin, Dana Backlund
    Ciombor, Kristen Keon
    Goff, Laura Williams
    Bradshaw, Marques
    Delbeke, Dominique
    Sandler, Martin P.
    Berlin, Jordan
    Ramirez, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Swiha, Mina M.
    Sutherland, Duncan E. K.
    Sistani, Golmehr
    Khatami, Alireza
    Abazid, Rami M.
    Mujoomdar, Amol
    Wiseman, Daniele P.
    Romsa, Jonathan G.
    Reid, Robert H.
    Laidley, David T.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (01) : 225 - 236
  • [4] Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
    Mina M. Swiha
    Duncan E. K. Sutherland
    Golmehr Sistani
    Alireza Khatami
    Rami M. Abazid
    Amol Mujoomdar
    Daniele P. Wiseman
    Jonathan G. Romsa
    Robert H. Reid
    David T. Laidley
    [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 225 - 236
  • [5] A Clinical Score (CS) for Well-Differentiated Neuroendocrine Tumor (WD-NET) Patients (Pts) Undergoing Peptide Receptor Radionuclide Therapy (PRRT)
    Das, S.
    Du, L.
    Schad, A.
    Jain, S.
    Jessop, A.
    Shah, C.
    Eisner, D.
    Cardin, D.
    Ciombor, K.
    Goff, L.
    Bradshaw, M.
    Delbeke, D.
    Sandler, M.
    Berlin, J.
    [J]. PANCREAS, 2021, 50 (03) : 452 - 452
  • [6] The outcome of peptide receptor radionuclide therapy (PRRT) in North American patients with advanced well-differentiated neuroendocrine tumors (WD-NETs).
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Combined use of 177Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study
    Fu, Jingjing
    Qiu, Fan
    Stolniceanu, Cati Raluca
    Yu, Fei
    Zang, Shiming
    Xiang, Yili
    Huang, Yue
    Matovic, Milovan
    Stefanescu, Cipriana
    Tang, Qiyun
    Wang, Feng
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (04)
  • [8] Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) with 177Lu-Dotatate (Lutathera) (LU) in neuroendocrine tumors (NETs)
    Navarro Martin, M.
    Teran Brage, E.
    Campana-Diaz, E.
    Garcia-Talavera, P.
    Reguera Puertas, P.
    Rama-Alonso, S.
    Garijo-Martinez, M. C.
    Felix, L. C.
    Diaz Sanchez, P.
    Vidal Tocino, R.
    Fonseca Sanchez, E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S95 - S95
  • [9] Treatment Response and Clinical Outcomes of Well-Differentiated (WD) High-Grade (HG) Neuroendocrine Tumors (NETs) to 177Lu-DOTATATE
    Coffman, Kelley
    Bodei, Lisa
    Le, Tiffany
    Choi, Ye
    Chou, Joanne
    Capanu, Marinela
    Dunphy, Mark
    Fox, Josef
    Grewal, Ravinder
    Reddy, Ryan
    Riedl, Christopher
    Schoder, Heiko
    Reidy-Lagunes, Diane
    Raj, Nitya
    [J]. PANCREAS, 2022, 51 (03) : E46 - E46
  • [10] The role of 177Lu-Dotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastrointestinal neuroendocrine tumors (GI-NETs)
    Severi, S.
    Sansovini, M.
    Ambrosetti, A.
    Ianniello, A.
    Scarpi, E.
    Nanni, O.
    Sarnelli, A.
    Di Iorio, V.
    Garaboldi, L.
    Matteucci, F.
    Bartolomei, M.
    Paganelli, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S233 - S233
12345